Brain metastasis from esophageal carcinoma

Agrawal, Rashmi; Shukla, Prity; Shukla, Vikas; Chauhan, Arvind

doi:10.4103/0973-1482.52785

Cited by 16 publications

(11 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, peripherally enhanced thin cyst walls (37/62, 59.7%) were more frequently observed compared to other common metastatic brain tumors. In Table 4, imaging features of brain metastases associated with esophageal carcinomas that have been published since 2004 [2,[11][12][13][14][15][16][17][18][19] are presented. In particular, cystic, enhanced tumors with minimal edema were notable.…”

Section: Discussionmentioning

confidence: 99%

“…After computed tomography (CT) had been introduced for clinical use in the 1970s, brain metastasis from esophageal carcinoma began to be reported clinically. [5][6][7][8]11,16] However, the majority of esophageal carcinoma reports were still based on autopsies. [9,10] With the clinical application of MRI, a larger number of reports of esophageal carcinoma have been published, [2][3][4][12][13][14][15][17][18][19] although, few reports have described both MRI findings and clinical features.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Neuroimaging and clinical characteristics of brain metastases from esophageal carcinoma in Chinese patients

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Neuroimaging and clinical characteristics of brain metastases from esophageal carcinoma in Chinese patients

et al. 2014

View full text Add to dashboard Cite

show abstract

“…However, the overall incidence of brain metastases in gastrointestinal cancers patients is relatively low [8,9,10]. Other reports that have pooled information either from several other clinical studies and autopsy studies [11] or only from autopsy series [12] have suggested that the frequency of brain metastases varies from 1 to 5% in all EC patients.…”

Section: Introductionmentioning

confidence: 99%

Incidence of Brain Metastases after Trimodality Therapy in Patients with Esophageal or Gastroesophageal Cancer: Implications for Screening and Surveillance

Wadhwa¹,

Takenaka²,

Correa³

et al. 2013

Oncology

View full text Add to dashboard Cite

Background: It is unclear whether patients undergoing trimodality therapy (TMT) should be screened or surveyed for brain metastases. Methods: We retrospectively analyzed esophageal cancer (EC) patients who underwent TMT between the years 2000 and 2010. All were systematically staged and surveyed but none had screening or surveillance brain imaging. Results: The median follow-up time for 518 patients was 29.3 months (range 1-149.2); all patients had adenocarcinoma of the esophagus. Of 188 (36.3%) patients who developed distant metastases, 20 (10.6% of 188 patients or 3.9% of 518 patients) had brain metastases. A higher baseline clinical stage (stage III or IVa) was associated with brain metastases. Most (90%) patients with brain metastases were diagnosed within 24 months of surgery. Sixteen patients had central nervous system symptoms at diagnosis. Twelve (60%) patients had solitary metastasis and 8 (40%) patients had multiple metastases. Although 17 patients received therapy for brain metastases, the median overall survival time of 20 patients was only 10.5 months (95% CI 6.6-14.0). Conclusion: After TMT, 3.9% of EC patients developed brain metastases and their prognosis was poor. Our data suggest that screening and/or surveillance for brain metastases in the EC population undergoing TMT is not warranted.

show abstract

“…However, the clinical outcome does not appear to be influenced by the presenting histology [34,36,41]. These rates do not differ from other BM in general [32,34,37,38]. Most patients die due to systemic disease, although patients with multiple BM tend to die due to neurological deterioration.…”

Section: Survival and Outcomementioning

confidence: 88%

“…The survival periods once PTC is diagnosed with a BM as well as its individual treatments are presented in Table 3. Table 2 Average survival periods in months following specific treatment of brain metastases originating from thyroid carcinoma [16,17,23,[115][116][117][118] [32][33][34]. In the Western population, esophageal adenocarcinomas are more frequent.…”

Section: Survival and Outcomementioning

confidence: 99%

Modern management of rare brain metastases in adults

et al. 2011

View full text Add to dashboard Cite

Brain metastases (BM) represent the main cause of intracranial neoplasms in adults, while being relatively less common in children. Today, better treatment options of the primary malignancy lead to higher remission rates as well as prolonged stable clinical conditions. This may in part explain the increased incidence of BM. Morbidity and mortality rates in patients with malignancies deteriorate significantly in cases of metastatic involvement of the central nervous system. Nowadays, especially modern management using surgical, medical, and radiotherapeutic options for treatment of BM tends to improve survival rates and enhance quality of life. Nonetheless, almost all treatment options are considered as palliative. In this review, we outline current knowledge of the incidence, diagnostic facilities, and therapeutic management of rare BM, with consideration of the basic aspects of the primary malignancy.

show abstract

Brain metastasis from esophageal carcinoma

Cited by 16 publications

References 6 publications

Neuroimaging and clinical characteristics of brain metastases from esophageal carcinoma in Chinese patients

Neuroimaging and clinical characteristics of brain metastases from esophageal carcinoma in Chinese patients

Incidence of Brain Metastases after Trimodality Therapy in Patients with Esophageal or Gastroesophageal Cancer: Implications for Screening and Surveillance

Modern management of rare brain metastases in adults

Contact Info

Product

Resources

About